Search - tctmd.com

Displaying 1 - 20 of 42

Sort: Relevancy | Date

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Todd Neale

September 18, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ideal CV Health at Age 50 Foretells Lower Risk of Later Dementia

Marcus A. Banks

August 12, 2019

News Daily News

CV Risk Factors in Youth May Prove Indelible for Later CAD

Marcus A. Banks

July 17, 2019

News Daily News

Silent MI Often Precedes Sudden Cardiac Death, Finnish Data Confirm

Caitlin E. Cox

July 15, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

News Daily News

Weight Training, Aerobic Exercise Affect Cardiac Fat Mass in Different Ways

Michael O'Riordan

July 05, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

Advertisement

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

Recurrent Events Common Among Young Patients With CAD

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Ideal CV Health at Age 50 Foretells Lower Risk of Later Dementia

CV Risk Factors in Youth May Prove Indelible for Later CAD

Silent MI Often Precedes Sudden Cardiac Death, Finnish Data Confirm

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Weight Training, Aerobic Exercise Affect Cardiac Fat Mass in Different Ways

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content